The opioid placebo analgesia is mediated exclusively through μ-opioid receptor in rat

International Journal of Neuropsychopharmacology

Volumn 16, Issue 4, 2013, Pages 849-856

  Zhang, Rui Rui ^a   Zhang, Wen Cai ^a   Wang, Jin Yan ^a   Guo, Jian You ^a  

^a INSTITUTE OF PSYCHOLOGY   (China)

Author keywords

opioid receptor; Placebo analgesia; rat; rostral anterior cingulate cortex

Indexed keywords

DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR CINGULATE; BRAIN REGION; CONTROLLED STUDY; LATENT PERIOD; MALE; MICROINJECTION; NONHUMAN; PAIN THRESHOLD; PLACEBO ANALGESIA; PLACEBO EFFECT; PRIORITY JOURNAL; RAT; REVIEW;

ANALGESIA; ANALGESICS, OPIOID; ANIMALS; GYRUS CINGULI; MALE; MICROINJECTIONS; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN THRESHOLD; PLACEBO EFFECT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU;

EID: 84875735542     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712000673     Document Type: Review

References (39)

1. Amanzio M, Benedetti F (1999). Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems vs. conditioning-activated specific subsystems. Journal of Neuroscience 19, 484-494.
2. Benedetti F (1996). The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia. Pain 64, 535-543.
3. Benedetti F, Amanzio M (1997). The neurobiology of placebo analgesia: from endogenous opioids to cholecystokinin. Progress in Neurobiology 52, 109-125.
4. Benedetti F, Amanzio M, Thoen W (2011). Disruption of opioid-induced placebo responses by activation of cholecystokinin type-2 receptors. Psychopharmacology 213, 791-797.
5. Benedetti F, Mayberg HS, Wager TD, Stohler CS, et al. (2005). Neurobiological mechanisms of the placebo effect. Journal of Neuroscience 25, 10390-10402.
6. Benedetti F, Pollo A, Colloca L (2007). Opioid-mediated placebo responses boost pain endurance and physical performance: is it doping in sport competitions? Journal of Neuroscience 27, 11934-11939.
7. Bennett MR (2010). Synapse regression in depression: the role of 5-HT receptors in modulating NMDA receptor function and synaptic plasticity. Australian and New Zealand Journal of Psychiatry 44, 301-308.
8. Bingel U, Lorenz J, Schoell E, Weiller C, et al. (2006). Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain 120, 8-15.
9. Boes AD, McCormick LM, Coryell WH, Nopoulos P (2008). Rostral anterior cingulate cortex volume correlates with depressed mood in normal healthy children. Biological Psychiatry 63, 391-397.
10. Broadbear JH, Negus SS, Butelman ER, de Costa BR, et al. (1994). Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay. Psychopharmacology 115, 311-319.
11. Carlino E, Pollo A, Benedetti F (2011). Placebo analgesia and beyond: a melting pot of concepts and ideas for neuroscience. Current Opinion on Anesthesiology 24, 540-544.
12. Colloca L, Benedetti F (2009). Placebo analgesia induced by social observational learning. Pain 144, 28-34.
13. Colloca L, Petrovic P, Wager TD, Ingvar M, et al. (2010). How the number of learning trials affects placebo and nocebo responses. Pain 151, 430-439.
14. Craggs JG, Price DD, Perlstein WM, Verne GN, et al. (2008). The dynamic mechanisms of placebo induced analgesia: evidence of sustained and transient regional involvement. Pain 139, 660-669.
15. Eippert F, Bingel U, Schoell E, Yacubian J, et al. (2008). Blockade of endogenous opioid neurotransmission enhances acquisition of conditioned fear in humans. Journal of Neuroscience 28, 5465-5472.
16. Eippert F, Bingel U, Schoell ED, Yacubian J, et al. (2009). Activation of the opioidergic descending pain control system underlies placebo analgesia. Neuron 63, 533-543.
17. Filliol D, Ghozland S, Chluba J, Martin M, et al. (2000). Mice deficient for delta-and mu-opioid receptors exhibit opposing alterations of emotional responses. Nature Genetics 25, 195-200.
18. Gracely RH, Dubner R, Wolskee PJ, Deeter WR (1983). Placebo and naloxone can alter post-surgical pain by separate mechanisms. Nature 306, 264-265.
19. Guo JY, Wang JY, Luo F (2010). Dissection of placebo analgesia in mice: the conditions for activation of opioid and non-opioid systems. Journal of Psychopharmacology 24, 1561-1567.
20. Guo JY, Yuan XY, Sui F, Zhang WC, et al. (2011). Placebo analgesia affects the behavioral despair tests and hormonal secretions in mice. Psychopharmacology 217, 83-90.
21. Kong J, Gollub RL, Rosman IS, Webb JM, et al. (2006). Brain activity associated with expectancy-enhanced placebo analgesia as measured by functional magnetic resonance imaging. Journal of Neuroscience 26, 381-388.
22. Levine JD, Gordon NC, Fields HL (1978). The mechanism of placebo analgesia. Lancet 2, 654-657.
23. Matthes HW, Maldonado R, Simonin F, Valverde O, et al. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383, 819-823.
24. Minami M, Satoh M (1995). Molecular biology of the opioid receptors: structures, functions and distributions. Neuroscience Research 23, 121-145.
25. Moles A, Kieffer BL, D'Amato FR (2004). Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science 304, 1983-1986.
26. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. London: Academic.
27. Petrovic P, Kalso E, Petersson KM, Ingvar M (2002). Placebo and opioid analgesia-imaging a shared neuronal network. Science 295, 1737-1740.
28. Pizzagalli DA (2011). Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 36, 183-206.
29. Price DD, Finniss DG, Benedetti F (2008). A comprehensive review of the placebo effect: recent advances and current thought. Annual Review of Psychology 59, 565-590.
30. Qiu YH, Wu XY, Xu H, Sackett D (2009). Neuroimaging study of placebo analgesia in humans. Neuroscience Bulletin 25, 277-282.
31. Quang PN, Schmidt BL (2010). Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice. Journal of Pain 11, 663-671.
32. Sarinopoulos I, Dixon GE, Short SJ, Davidson RJ, et al. (2006). Brain mechanisms of expectation associated with insula and amygdala response to aversive taste: implications for placebo. Brain, Behavior, and Immunity 20, 120-132.
33. Schiff N, Ribary U, Plum F, Llinas R (1999). Words without mind. Journal of Cognitive Neuroscience 11, 650-656.
34. Scott DJ, Stohler CS, Egnatuk CM, Wang H, et al. (2008). Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Archives of General Psychiatry 65, 220-231.
35. Steinmiller CL, Young AM (2008). Pharmacological selectivity of CTAP in a warm water tail-withdrawal antinociception assay in rats. Psychopharmacology (Berlin) 195, 497-507.
36. Wager TD, Rilling JK, Smith EE, Sokolik A, et al. (2004). Placebo-induced changes in FMRI in the anticipation and experience of pain. Science 303, 1162-1167.
37. Wager TD, Scott DJ, Zubieta JK (2007). Placebo effects on human mu-opioid activity during pain. Proceedings of the National Academy of Sciences USA 104, 11056-11061.
38. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, et al. (2005). Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. Journal of Neuroscience 25, 7754-7762.
39. Zubieta JK, Ketter TA, Bueller JA, Xu Y, et al. (2003). Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission. Archives of General Psychiatry 60, 1145-1153.